This chemical is primarily utilized in the field of targeted protein degradation, a cutting-edge approach in drug discovery and therapeutic development. It functions as a key component in the design of PROTACs (Proteolysis Targeting Chimeras), which are bifunctional molecules that recruit E3 ubiquitin ligases to specific target proteins, leading to their ubiquitination and subsequent degradation by the proteasome. This mechanism is particularly valuable in addressing diseases caused by the overexpression or malfunction of specific proteins, such as cancer, neurodegenerative disorders, and autoimmune conditions. Its application enables the selective elimination of disease-causing proteins, offering a novel strategy for tackling previously "undruggable" targets. Additionally, it is employed in research to study protein function and validate potential therapeutic targets in cellular and preclinical models.